Background {#Sec1}
==========

In the twentieth century, pioneering works by distinguished professors Cochrane A \[[@CR1]\], Guyatt GH \[[@CR2]\], and Chalmers IG \[[@CR3]\] have led us to the evidence-based medicine (EBM) era. In this era, how to search, critically appraise, and use the best evidence is important. Moreover, systematic review and meta-analysis is the most used tool for summarizing primary data scientifically \[[@CR4]--[@CR6]\] and also the basic for developing clinical practice guideline according to the Institute of Medicine (IOM) \[[@CR7]\]. Hence, to perform a systematic review and/ or meta-analysis, assessing the methodological quality of based primary studies is important; naturally, it would be key to assess its own methodological quality before usage. Quality includes internal and external validity, while methodological quality usually refers to internal validity \[[@CR8], [@CR9]\]. Internal validity is also recommended as "risk of bias (RoB)" by the Cochrane Collaboration \[[@CR9]\].

There are three types of tools: scales, checklists, and items \[[@CR10], [@CR11]\]. In 2015, Zeng et al. \[[@CR11]\] investigated methodological quality tools for randomized controlled trial (RCT), non-randomized clinical intervention study, cohort study, case-control study, cross-sectional study, case series, diagnostic accuracy study which also called "diagnostic test accuracy (DTA)", animal study, systematic review and meta-analysis, and clinical practice guideline (CPG). From then on, some changes might generate in pre-existing tools, and new tools might also emerge; moreover, the research method has also been developed in recent years. Hence, it is necessary to systematically investigate commonly-used tools for assessing methodological quality, especially those for economic evaluation, clinical prediction rule/model, and qualitative study. Therefore, this narrative review presented related methodological quality (including "RoB") assessment tools for primary and secondary medical studies up to December 2019, and Table [1](#Tab1){ref-type="table"} presents their basic characterizes. We hope this review can help the producers, users, and researchers of evidence. Table 1The basic characteristics of the included methodological quality (risk of bias) assessment toolsNo.Development OrganizationTool's nameType of study1The Cochrane CollaborationCochrane RoB tool and RoB 2.0 toolRandomized controlled trialDiagnostic accuracy study2The Physiotherapy Evidence Database (PEDro)PEDro scaleRandomized controlled trial3The Effective Practice and Organisation of Care (EPOC) GroupEPOC RoB toolRandomized controlled trialClinical controlled trialsControlled before-and-after studyInterrupted time series studies4The Critical Appraisal Skills Programme (CASP)CASP checklistRandomized controlled trialCohort studyCase-control studyCross-sectional studyDiagnostic test studyClinical prediction ruleEconomic evaluationQualitative studySystematic review5The National Institutes of Health (NIH)NIH quality assessment toolControlled intervention studyCohort studyCross-sectional studyCase-control studyBefore-after (Pre-post) study with no control groupCase-series (Interventional)Systematic review and meta-analysis6The Joanna Briggs Institute (JBI)JBI critical appraisal checklistRandomized controlled trialNon-randomized experimental studyCohort studyCase-control studyCross-sectional studyPrevalence dataCase reportsEconomic evaluationQualitative studyText and expert opinion papersSystematic reviews and research syntheses7The Scottish Intercollegiate Guidelines Network (SIGN)SIGN methodology checklistRandomized controlled trialCohort studyCase-control studyDiagnostic studyEconomic evaluationSystematic reviews and meta-analyses8The Stroke Therapy Academic Industry Roundtable (STAIR) GroupCAMARADES toolAnimal study9The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE)SYRCLE's RoB toolAnimal study10Sterne JAC et al.ROBINS-I toolNon-randomised interventional study11Slim K et al.MINORS toolNon-randomised interventional study12The Canada Institute of Health Economics (IHE)IHE quality appraisal toolCase-series (Interventional)13Wells GA et al.Newcastle-Ottawa Scale (NOS)Cohort studyCase-control study14Downes MJ et al.AXIS toolCross-sectional study15The Agency for Healthcare Research and Quality (AHRQ)AHRQ methodology checklistCross-sectional/ Prevalence study16Crombie ICrombie's itemsCross-sectional study17The Good Research for Comparative Effectiveness (GRACE) InitiativeGRACE checklistComparative effectiveness research18Whiting PF et al.QUADAS tool and QUADAS-2 toolDiagnostic accuracy study19The National Institute for Clinical Excellence (NICE)NICE methodology checklistEconomic evaluation20The Cabinet OfficeThe Quality Framework: Cabinet Office checklistQualitative study (social research)21Hayden JA et al.QIPS toolPrediction study (predictor finding study)22Wolff RF et al.PROBASTPrediction study (prediction model study)23The (COnsensus-based Standards for the selection of health Measurement INstruments) initiativeCOSMIN RoB checklistPatient-reported outcome measure developmentContent validityStructural validityInternal consistencyCross-cultural validity/ measurement invarianceReliabilityMeasurement errorCriterion validityHypotheses testing for construct validityResponsiveness24Shea BJ et al.AMSTAR and AMSTAR 2Systematic review25The Decision Support Unit (DSU)DSU network meta-analysis (NMA) methodology checklistNetwork meta-analysis26Whiting P et al.ROBIS toolSystematic review27Brouwers MC et al.AGREE instrument and AGREE II instrumentClinical practice guideline*AMSTAR* A measurement tool to assess systematic reviews, *AHRQ* Agency for healthcare research and quality, *AXIS* Appraisal tool for cross-sectional studies, *CASP* Critical appraisal skills programme, *CAMARADES* The collaborative approach to meta-analysis and review of animal data from experimental studies, *COSMIN* Consensus-based standards for the selection of health measurement instruments, *DSU* Decision support unit, *EPOC* the effective practice and organisation of care group, *GRACE* The god research for comparative effectiveness initiative, *IHE* Canada institute of health economics, *JBI* Joanna Briggs Institute, *MINORS* Methodological index for non-randomized studies, *NOS* Newcastle-Ottawa scale, *NMA* network meta-analysis, *NIH* national institutes of health, *NICE* National institute for clinical excellence, *PEDro* physiotherapy evidence database, *PROBAST* The prediction model risk of bias assessment tool, *QUADAS* Quality assessment of diagnostic accuracy studies, *QIPS* Quality in prognosis studies, *RoB* Risk of bias, *ROBINS-I* Risk of bias in non-randomised studies - of interventions, *ROBIS* Risk of bias in systematic review, *SYRCLE* Systematic review center for laboratory animal experimentation, *STAIR* Stroke therapy academic industry roundtable, *SIGN* The Scottish intercollegiate guidelines network

Tools for intervention studies {#Sec2}
==============================

Randomized controlled trial (individual or cluster) {#Sec3}
---------------------------------------------------

The first RCT was designed by Hill BA (1897--1991) and became the "gold standard" for experimental study design \[[@CR12], [@CR13]\] up to now. Nowadays, the Cochrane risk of bias tool for randomized trials (which was introduced in 2008 and edited on March 20, 2011) is the most commonly recommended tool for RCT \[[@CR9], [@CR14]\], which is called "RoB". On August 22, 2019 (which was introduced in 2016), the revised revision for this tool to assess RoB in randomized trials (RoB 2.0) was published \[[@CR15]\]. The RoB 2.0 tool is suitable for individually-randomized, parallel-group, and cluster- randomized trials, which can be found in the dedicated website <https://www.riskofbias.info/welcome/rob-2-0-tool>. The RoB 2.0 tool consists of five bias domains and shows major changes when compared to the original Cochrane RoB tool (Table S[1](#MOESM1){ref-type="media"}A-B presents major items of both versions).

The Physiotherapy Evidence Database (PEDro) scale is a specialized methodological assessment tool for RCT in physiotherapy \[[@CR16], [@CR17]\] and can be found in <http://www.pedro.org.au/english/downloads/pedro-scale/>, covering 11 items (Table S[1](#MOESM1){ref-type="media"}C). The Effective Practice and Organisation of Care (EPOC) Group is a Cochrane Review Group who also developed a tool (called as "EPOC RoB Tool") for complex interventions randomized trials. This tool has 9 items (Table S[1](#MOESM1){ref-type="media"}D) and can be found in <https://epoc.cochrane.org/resources/epoc-resources-review-authors>. The Critical Appraisal Skills Programme (CASP) is a part of the Oxford Centre for Triple Value Healthcare Ltd. (3 V) portfolio, which provides resources and learning and development opportunities to support the development of critical appraisal skills in the UK (<http://www.casp-uk.net/>) \[[@CR18]--[@CR20]\]. The CASP checklist for RCT consists of three sections involving 11 items (Table S[1](#MOESM1){ref-type="media"}E). The National Institutes of Health (NIH) also develops quality assessment tools for controlled intervention study (Table S[1](#MOESM1){ref-type="media"}F) to assess methodological quality of RCT (<https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>).

The Joanna Briggs Institute (JBI) is an independent, international, not-for-profit researching and development organization based in the Faculty of Health and Medical Sciences at the University of Adelaide, South Australia (<https://joannabriggs.org/>). Hence, it also develops many critical appraisal checklists involving the feasibility, appropriateness, meaningfulness and effectiveness of healthcare interventions. Table S[1](#MOESM1){ref-type="media"}G presents the JBI Critical appraisal checklist for RCT, which includes 13 items.

The Scottish Intercollegiate Guidelines Network (SIGN) was established in 1993 (<https://www.sign.ac.uk/>). Its objective is to improve the quality of health care for patients in Scotland via reducing variations in practices and outcomes, through developing and disseminating national clinical guidelines containing recommendations for effective practice based on current evidence. Hence, it also develops many critical appraisal checklists for assessing methodological quality of different study types, including RCT (Table S[1](#MOESM1){ref-type="media"}H).

In addition, the Jadad Scale \[[@CR21]\], Modified Jadad Scale \[[@CR22], [@CR23]\], Delphi List \[[@CR24]\], Chalmers Scale \[[@CR25]\], National Institute for Clinical Excellence (NICE) methodology checklist \[[@CR11]\], Downs & Black checklist \[[@CR26]\], and other tools summarized by West et al. in 2002 \[[@CR27]\] are not commonly used or recommended nowadays.

Animal study {#Sec4}
------------

Before starting clinical trials, the safety and effectiveness of new drugs are usually tested in animal models \[[@CR28]\], so animal study is considered as preclinical research, possessing important significance \[[@CR29], [@CR30]\]. Likewise, the methodological quality of animal study also needs to be assessed \[[@CR30]\]. In 1999, the initial "Stroke Therapy Academic Industry Roundtable (STAIR)" recommended their criteria for assessing the quality of stroke animal studies \[[@CR31]\] and this tool is also called "STAIR". In 2009, the STAIR Group updated their criteria and developed "Recommendations for Ensuring Good Scientific Inquiry" \[[@CR32]\]. Besides, Macleod et al. \[[@CR33]\] proposed a 10-point tool based on STAIR to assess methodological quality of animal study in 2004, which is also called "CAMARADES (The Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies)"; with "S" presenting "Stroke" at that time and now standing for "Studies" (<http://www.camarades.info/>). In CAMARADES tool, every item could reach a highest score of one point and the total score for this tool could achieve 10 points (Table S[1](#MOESM1){ref-type="media"}J).

In 2008, the Systematic Review Center for Laboratory animal Experimentation (SYRCLE) was established in Netherlands and this team developed and released an RoB tool for animal intervention studies - SYRCLE's RoB tool in 2014, based on the original Cochrane RoB Tool \[[@CR34]\]. This new tool contained 10 items which had become the most recommended tool for assessing the methodological quality of animal intervention studies (Table S[1](#MOESM1){ref-type="media"}I).

Non-randomised studies {#Sec5}
----------------------

In clinical research, RCT is not always feasible \[[@CR35]\]; therefore, non-randomized design remains considerable. In non-randomised study (also called quasi-experimental studies), investigators control the allocation of participants into groups, but do not attempt to adopt randomized operation \[[@CR36]\], including follow-up study. According to with or without comparison, non-randomized clinical intervention study can be divided into comparative and non-comparative sub-types, the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool \[[@CR37]\] is the preferentially recommended tool. This tool is developed to evaluate risk of bias in estimating comparative effectiveness (harm or benefit) of interventions in studies not adopting randomization in allocating units (individuals or clusters of individuals) into comparison groups. Besides, the JBI critical appraisal checklist for quasi-experimental studies (non-randomized experimental studies) is also suitable, which includes 9 items. Moreover, the methodological index for non-randomized studies (MINORS) \[[@CR38]\] tool can also be used, which contains a total of 12 methodological points; the first 8 items could be applied for both non-comparative and comparative studies, while the last 4 items appropriate for studies with two or more groups. Every item is scored from 0 to 2, and the total scores over 16 or 24 give an overall quality score. Table S[1](#MOESM1){ref-type="media"}K-L-M presented the major items of these three tools.

Non-randomized study with a separate control group could also be called clinical controlled trial or controlled before-and-after study. For this design type, the EPOC RoB tool is suitable (see Table S[1](#MOESM1){ref-type="media"}D). When using this tool, the "random sequence generation" and "allocation concealment" should be scored as "High risk", while grading for other items could be the same as that for randomized trial.

Non-randomized study without a separate control group could be a before-after (Pre-Post) study, a case series (uncontrolled longitudinal study), or an interrupted time series study. A case series is described a series of individuals, who usually receive the same intervention, and contains non control group \[[@CR9]\]. There are several tools for assessing the methodological quality of case series study. The latest one was developed by Moga C et al. \[[@CR39]\] in 2012 using a modified Delphi technique, which was developed by the Canada Institute of Health Economics (IHE); hence, it is also called "IHE Quality Appraisal Tool" (Table S[1](#MOESM1){ref-type="media"}N). Moreover, NIH also develops a quality assessment tool for case series study, including 9 items (Table S[1](#MOESM1){ref-type="media"}O). For interrupted time series studies, the "EPOC RoB tool for interrupted time series studies" is recommended (Table S[1](#MOESM1){ref-type="media"}P). For the before-after study, we recommend the NIH quality assessment tool for before-after (Pre-Post) study without control group (Table S[1](#MOESM1){ref-type="media"}Q).

In addition, for non-randomized intervention study, the Reisch tool (Check List for Assessing Therapeutic Studies) \[[@CR11], [@CR40]\], Downs & Black checklist \[[@CR26]\], and other tools summarized by Deeks et al. \[[@CR36]\] are not commonly used or recommended nowadays.

Tools for observational studies and diagnostic study {#Sec6}
====================================================

Observational studies include cohort study, case-control study, cross-sectional study, case series, case reports, and comparative effectiveness research \[[@CR41]\], and can be divided into analytical and descriptive studies \[[@CR42]\].

Cohort study {#Sec7}
------------

Cohort study includes prospective cohort study, retrospective cohort study, and ambidirectional cohort study \[[@CR43]\]. There are some tools for assessing the quality of cohort study, such as the CASP cohort study checklist (Table S[2](#MOESM2){ref-type="media"}A), SIGN critical appraisal checklists for cohort study (Table S[2](#MOESM2){ref-type="media"}B), NIH quality assessment tool for observational cohort and cross-sectional studies (Table S[2](#MOESM2){ref-type="media"}C), Newcastle-Ottawa Scale (NOS; Table S[2](#MOESM2){ref-type="media"}D) for cohort study, and JBI critical appraisal checklist for cohort study (Table S[2](#MOESM2){ref-type="media"}E). However, the Downs & Black checklist \[[@CR26]\] and the NICE methodology checklist for cohort study \[[@CR11]\] are not commonly used or recommended nowadays.

The NOS \[[@CR44], [@CR45]\] came from an ongoing collaboration between the Universities of Newcastle, Australia and Ottawa, Canada. Among all above mentioned tools, the NOS is the most commonly used tool nowadays which also allows to be modified based on a special subject.

Case-control study {#Sec8}
------------------

Case-control study selects participants based on the presence of a specific disease or condition, and seeks earlier exposures that may lead to the disease or outcome \[[@CR42]\]. It has an advantage over cohort study, that is the issue of "drop out" or "loss in follow up" of participants as seen in cohort study would not arise in such study. Nowadays, there are some acceptable tools for assessing the methodological quality of case-control study, including CASP case-control study checklist (Table S[2](#MOESM2){ref-type="media"}F), SIGN critical appraisal checklists for case-control study (Table S[2](#MOESM2){ref-type="media"}G), NIH quality assessment tool of case-control study (Table S[2](#MOESM2){ref-type="media"}H), JBI critical appraisal checklist for case-control study (Table S[2](#MOESM2){ref-type="media"}I), and the NOS for case-control study (Table S[2](#MOESM2){ref-type="media"}J). Among them, the NOS for case-control study is also the most frequently used tool nowadays and allows to be modified by users.

In addition, the Downs & Black checklist \[[@CR26]\] and the NICE methodology checklist for case-control study \[[@CR11]\] are also not commonly used or recommended nowadays.

Cross-sectional study (analytical or descriptive) {#Sec9}
-------------------------------------------------

Cross-sectional study is used to provide a snapshot of a disease and other variables in a defined population at a time point. It can be divided into analytical and purely descriptive types. Descriptive cross-sectional study merely describes the number of cases or events in a particular population at a time point or during a period of time; whereas analytic cross-sectional study can be used to infer relationships between a disease and other variables \[[@CR46]\].

For assessing the quality of analytical cross-sectional study, the NIH quality assessment tool for observational cohort and cross-sectional studies (Table S[2](#MOESM2){ref-type="media"}C), JBI critical appraisal checklist for analytical cross-sectional study (Table S[2](#MOESM2){ref-type="media"}K), and the Appraisal tool for Cross-Sectional Studies (AXIS tool; Table S[2](#MOESM2){ref-type="media"}L) \[[@CR47]\] are recommended tools. The AXIS tool is a critical appraisal tool that addresses study design and reporting quality as well as the risk of bias in cross-sectional study, which was developed in 2016 and contains 20 items. Among these three tools, the JBI checklist is the most preferred one.

Purely descriptive cross-sectional study is usually used to measure disease prevalence and incidence. Hence, the critical appraisal tool for analytic cross-sectional study is not proper for the assessment. Only few quality assessment tools are suitable for descriptive cross-sectional study, like the JBI critical appraisal checklist for studies reporting prevalence data \[[@CR48]\] (Table S[2](#MOESM2){ref-type="media"}M), Agency for Healthcare Research and Quality (AHRQ) methodology checklist for assessing the quality of cross-sectional/ prevalence study (Table S[2](#MOESM2){ref-type="media"}N), and Crombie's items for assessing the quality of cross-sectional study \[[@CR49]\] (Table S[2](#MOESM2){ref-type="media"}O). Among them, the JBI tool is the newest.

Case series and case reports {#Sec10}
----------------------------

Unlike above mentioned interventional case series, case reports and case series are used to report novel occurrences of a disease or a unique finding \[[@CR50]\]. Hence, they belong to descriptive studies. There is only one tool -- the JBI critical appraisal checklist for case reports (Table S[2](#MOESM2){ref-type="media"}P).

Comparative effectiveness research {#Sec11}
----------------------------------

Comparative effectiveness research (CER) compares real-world outcomes \[[@CR51]\] resulting from alternative treatment options that are available for a given medical condition. Its key elements include the study of effectiveness (effect in the real world), rather than efficacy (ideal effect), and the comparisons among alternative strategies \[[@CR52]\]. In 2010, the Good Research for Comparative Effectiveness (GRACE) Initiative was established and developed principles to help healthcare providers, researchers, journal readers, and editors evaluate inherent quality for observational research studies of comparative effectiveness \[[@CR41]\]. And in 2016, a validated assessment tool -- the GRACE Checklist v5.0 (Table S[2](#MOESM2){ref-type="media"}Q) was released for assessing the quality of CER.

Diagnostic study {#Sec12}
----------------

Diagnostic tests, also called "Diagnostic Test Accuracy (DTA)", are used by clinicians to identify whether a condition exists in a patient or not, so as to develop an appropriate treatment plan \[[@CR53]\]. DTA has several unique features in terms of its design which differ from standard intervention and observational evaluations. In 2003, Penny et al. \[[@CR53], [@CR54]\] developed a tool for assessing the quality of DTA, namely Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. In 2011, a revised "QUADAS-2" tool (Table S[2](#MOESM2){ref-type="media"}R) was launched \[[@CR55], [@CR56]\]. Besides, the CASP diagnostic checklist (Table S[2](#MOESM2){ref-type="media"}S), SIGN critical appraisal checklists for diagnostic study (Table S[2](#MOESM2){ref-type="media"}T), JBI critical appraisal checklist for diagnostic test accuracy studies (Table S[2](#MOESM2){ref-type="media"}U), and the Cochrane risk of bias assessing tool for diagnostic test accuracy (Table S[2](#MOESM2){ref-type="media"}V) are also common useful tools in this field.

Of them, the Cochrane risk of bias tool (<https://methods.cochrane.org/sdt/>) is based on the QUADAS tool, and the SIGN and JBI tools are based on the QUADAS-2 tool. Of course, the QUADAS-2 tool is the first recommended tool. Other relevant tools reviewed by Whiting et al. \[[@CR53]\] in 2004 are not used nowadays.

Tools for other primary medical studies {#Sec13}
=======================================

Health economic evaluation {#Sec14}
--------------------------

Health economic evaluation research comparatively analyses alternative interventions with regard to their resource uses, costs and health effects \[[@CR57]\]. It focuses on identifying, measuring, valuing and comparing resource use, costs and benefit/effect consequences for two or more alternative intervention options \[[@CR58]\]. Nowadays, health economic study is increasingly popular. Of course, its methodological quality also needs to be assessed before its initiation. The first tool for such assessment was developed by Drummond and Jefferson in 1996 \[[@CR59]\], and then many tools have been developed based on the Drummond's items or its revision \[[@CR60]\], such as the SIGN critical appraisal checklists for economic evaluations (Table S[3](#MOESM3){ref-type="media"}A), CASP economic evaluation checklist (Table S[3](#MOESM3){ref-type="media"}B), and the JBI critical appraisal checklist for economic evaluations (Table S[3](#MOESM3){ref-type="media"}C). The NICE only retains one methodology checklist for economic evaluation (Table S[3](#MOESM3){ref-type="media"}D).

However, we regard the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement \[[@CR61]\] as a reporting tool rather than a methodological quality assessment tool, so we do not recommend it to assess the methodological quality of health economic evaluation.

Qualitative study {#Sec15}
-----------------

In healthcare, qualitative research aims to understand and interpret individual experiences, behaviours, interactions, and social contexts, so as to explain interested phenomena, such as the attitudes, beliefs, and perspectives of patients and clinicians; the interpersonal nature of caregiver and patient relationships; illness experience; and the impact of human sufferings \[[@CR62]\]. Compared with quantitative studies, assessment tools for qualitative studies are fewer. Nowadays, the CASP qualitative research checklist (Table S[3](#MOESM3){ref-type="media"}E) is the most frequently recommended tool for this issue. Besides, the JBI critical appraisal checklist for qualitative research \[[@CR63], [@CR64]\] (Table S[3](#MOESM3){ref-type="media"}F) and the Quality Framework: Cabinet Office checklist for social research \[[@CR65]\] (Table S[3](#MOESM3){ref-type="media"}G) are also suitable.

Prediction studies {#Sec16}
------------------

Clinical prediction study includes predictor finding (prognostic factor) studies, prediction model studies (development, validation, and extending or updating), and prediction model impact studies \[[@CR66]\]. For predictor finding study, the Quality In Prognosis Studies (QIPS) tool \[[@CR67]\] can be used for assessing its methodological quality (Table S[3](#MOESM3){ref-type="media"}H). For prediction model impact studies, if it uses a randomized comparative design, tools for RCT can be used, especially the RoB 2.0 tool; if it uses a nonrandomized comparative design, tools for non-randomized studies can be used, especially the ROBINS-I tool. For diagnostic and prognostic prediction model studies, the Prediction model Risk Of Bias Assessment Tool (PROBAST; Table S[3](#MOESM3){ref-type="media"}I) \[[@CR68]\] and CASP clinical prediction rule checklist (Table S[3](#MOESM3){ref-type="media"}J) are suitable.

Text and expert opinion papers {#Sec17}
------------------------------

Text and expert opinion-based evidence (also called "non-research evidence") comes from expert opinions, consensus, current discourse, comments, and assumptions or assertions that appear in various journals, magazines, monographs and reports \[[@CR69]--[@CR71]\]. Nowadays, only the JBI has a critical appraisal checklist for the assessment of text and expert opinion papers (Table S[3](#MOESM3){ref-type="media"}K).

Outcome measurement instruments {#Sec18}
-------------------------------

An outcome measurement instrument is a "device" used to collect a measurement. The range embraced by the term 'instrument' is broad, and can refer to questionnaire (e.g. patient-reported outcome such as quality of life), observation (e.g. the result of a clinical examination), scale (e.g. a visual analogue scale), laboratory test (e.g. blood test) and images (e.g. ultrasound or other medical imaging) \[[@CR72], [@CR73]\]. Measurements can be subjective or objective, and either unidimensional (e.g. attitude) or multidimensional. Nowadays, only one tool - the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) Risk of Bias checklist \[[@CR74]--[@CR76]\] ([www.cosmin.nl/](http://www.cosmin.nl/)) is proper for assessing the methodological quality of outcome measurement instrument, and Table S[3](#MOESM3){ref-type="media"}L presents its major items, including patient - reported outcome measure (PROM) development (Table S[3](#MOESM3){ref-type="media"}LA), content validity (Table S[3](#MOESM3){ref-type="media"}LB), structural validity (Table S[3](#MOESM3){ref-type="media"}LC), internal consistency (Table S[3](#MOESM3){ref-type="media"}LD), cross-cultural validity/ measurement invariance (Table S[3](#MOESM3){ref-type="media"}LE), reliability (Table S[3](#MOESM3){ref-type="media"}LF), measurement error (Table S[3](#MOESM3){ref-type="media"}LG), criterion validity (Table S[3](#MOESM3){ref-type="media"}LH), hypotheses testing for construct validity (Table S[3](#MOESM3){ref-type="media"}LI), and responsiveness (Table S[3](#MOESM3){ref-type="media"}LJ).

Tools for secondary medical studies {#Sec19}
===================================

Systematic review and meta-analysis {#Sec20}
-----------------------------------

Systematic review and meta-analysis are popular methods to keep up with current medical literature \[[@CR4]--[@CR6]\]. Their ultimate purposes and values lie in promoting healthcare \[[@CR6], [@CR77], [@CR78]\]. Meta-analysis is a statistical process of combining results from several studies, commonly a part of a systematic review \[[@CR11]\]. Of course, critical appraisal would be necessary before using systematic review and meta-analysis.

In 1988, Sacks et al. developed the first tool for assessing the quality of meta-analysis on RCTs - the Sack's Quality Assessment Checklist (SQAC) \[[@CR79]\]; And then in 1991, Oxman and Guyatt developed another tool -- the Overview Quality Assessment Questionnaire (OQAQ) \[[@CR80], [@CR81]\]. To overcome the shortcomings of these two tools, in 2007 the A Measurement Tool to Assess Systematic Reviews (AMSTAR) was developed based on them \[[@CR82]\] (<http://www.amstar.ca/>). However, this original AMSTAR instrument did not include an assessment on the risk of bias for non-randomised studies, and the expert group thought revisions should address all aspects of the conduct of a systematic review. Hence, the new instrument for randomised or non-randomised studies on healthcare interventions - AMSTAR 2 was released in 2017 \[[@CR83]\], and Table S[4](#MOESM4){ref-type="media"}A presents its major items.

Besides, the CASP systematic review checklist (Table S[4](#MOESM4){ref-type="media"}B), SIGN critical appraisal checklists for systematic reviews and meta-analyses (Table S[4](#MOESM4){ref-type="media"}C), JBI critical appraisal checklist for systematic reviews and research syntheses (Table S[4](#MOESM4){ref-type="media"}D), NIH quality assessment tool for systematic reviews and meta-analyses (Table S[4](#MOESM4){ref-type="media"}E), The Decision Support Unit (DSU) network meta-analysis (NMA) methodology checklist (Table S[4](#MOESM4){ref-type="media"}F), and the Risk of Bias in Systematic Review (ROBIS) \[[@CR84]\] tool (Table S[4](#MOESM4){ref-type="media"}G) are all suitable. Among them, the AMSTAR 2 is the most commonly used and the ROIBS is the most frequently recommended.

Among those tools, the AMSTAR 2 is suitable for assessing systematic review and meta-analysis based on randomised or non-randomised interventional studies, the DSU NMA methodology checklist for network meta-analysis, while the ROBIS for meta-analysis based on interventional, diagnostic test accuracy, clinical prediction, and prognostic studies.

Clinical practice guidelines {#Sec21}
----------------------------

Clinical practice guideline (CPG) is integrated well into the thinking of practicing clinicians and professional clinical organizations \[[@CR85]--[@CR87]\]; and also make scientific evidence incorporated into clinical practice \[[@CR88]\]. However, not all CPGs are evidence-based \[[@CR89], [@CR90]\] and their qualities are uneven \[[@CR91]--[@CR93]\]. Until now there were more than 20 appraisal tools have been developed \[[@CR94]\]. Among them, the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument has the greatest potential in serving as a basis to develop an appraisal tool for clinical pathways \[[@CR94]\]. The AGREE instrument was first released in 2003 \[[@CR95]\] and updated to AGREE II instrument in 2009 \[[@CR96]\] ([www.agreetrust.org/](http://www.agreetrust.org/)). Now the AGREE II instrument is the most recommended tool for CPG (Table S[4](#MOESM4){ref-type="media"}H).

Besides, based on the AGREE II, the AGREE Global Rating Scale (AGREE GRS) Instrument \[[@CR97]\] was developed as a short item tool to evaluate the quality and reporting of CPGs.

Discussion and conclusions {#Sec22}
==========================

Currently, the EBM is widely accepted and the major attention of healthcare workers lies in "Going from evidence to recommendations" \[[@CR98], [@CR99]\]. Hence, critical appraisal of evidence before using is a key point in this process \[[@CR100], [@CR101]\]. In 1987, Mulrow CD \[[@CR102]\] pointed out that medical reviews needed routinely use scientific methods to identify, assess, and synthesize information. Hence, perform methodological quality assessment is necessary before using the study. However, although there are more than 20 years have been passed since the first tool emergence, many users remain misunderstand the methodological quality and reporting quality. Of them, someone used the reporting checklist to assess the methodological quality, such as used the Consolidated Standards of Reporting Trials (CONSORT) statement \[[@CR103]\] to assess methodological quality of RCT, used the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement \[[@CR104]\] to methodological quality of cohort study. This phenomenon indicates more universal education of clinical epidemiology is needed for medical students and professionals.

The methodological quality tool development should according to the characteristics of different study types. In this review, we used "methodological quality", "risk of bias", "critical appraisal", "checklist", "scale", "items", and "assessment tool" to search in the NICE website, SIGN website, Cochrane Library website and JBI website, and on the basis of them, added "systematic review", "meta-analysis", "overview" and "clinical practice guideline" to search in PubMed. Compared with our previous systematic review \[[@CR11]\], we found some tools are recommended and remain used, some are used without recommendation, and some are eliminated \[[@CR10], [@CR29], [@CR30], [@CR36], [@CR53], [@CR94], [@CR105]--[@CR107]\]. These tools produce a significant impetus for clinical practice \[[@CR108], [@CR109]\].

In addition, compared with our previous systematic review \[[@CR11]\], this review stated more tools, especially those developed after 2014, and the latest revisions. Of course, we also adjusted the method of study type classification. Firstly, in 2014, the NICE provided 7 methodology checklists but only retains and updated the checklist for economic evaluation now. Besides, the Cochrane RoB 2.0 tool, AMSTAR 2 tool, CASP checklist, and most of JBI critical appraisal checklists are all the newest revisions; the NIH quality assessment tool, ROBINS-I tool, EPOC RoB tool, AXIS tool, GRACE Checklist, PROBAST, COSMIN Risk of Bias checklist, and ROBIS tool are all newly released tools. Secondly, we also introduced tools for network meta-analysis, outcome measurement instruments, text and expert opinion papers, prediction studies, qualitative study, health economic evaluation, and CER. Thirdly, we classified interventional studies into randomized and non-randomized sub-types, and then further classified non-randomized studies into with and without controlled group. Moreover, we also classified cross-sectional study into analytic and purely descriptive sub-types, and case-series into interventional and observational sub-types. These processing courses were more objective and comprehensive.

Obviously, the number of appropriate tools is the largest for RCT, followed by cohort study; the applicable range of JBI is widest \[[@CR63], [@CR64]\], with CASP following closely. However, further efforts remain necessary to develop appraisal tools. For some study types, only one assessment tool is suitable, such as CER, outcome measurement instruments, text and expert opinion papers, case report, and CPG. Besides, there is no proper assessment tool for many study types, such as overview, genetic association study, and cell study. Moreover, existing tools have not been fully accepted. In the future, how to develop well accepted tools remains a significant and important work \[[@CR11]\].

Our review can help the professionals of systematic review, meta-analysis, guidelines, and evidence users to choose the best tool when producing or using evidence. Moreover, methodologists can obtain the research topics for developing new tools. Most importantly, we must remember that all assessment tools are subjective, and actual yields of wielding them would be influenced by user's skills and knowledge level. Therefore, users must receive formal training (relevant epidemiological knowledge is necessary), and hold rigorous academic attitude, and at least two independent reviewers should be involved in evaluation and cross-checking to avoid performance bias \[[@CR110]\].
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AGREE GRS

:   AGREE Global rating scale

AGREE

:   Appraisal of guidelines for research and evaluation

AHRQ

:   Agency for healthcare research and quality

AMSTAR

:   A measurement tool to assess systematic reviews

AXIS

:   Appraisal tool for cross-sectional studies

CAMARADES

:   The collaborative approach to meta-analysis and review of animal data from experimental studies

CASP

:   Critical appraisal skills programme

CER

:   Comparative effectiveness research

CHEERS

:   Consolidated health economic evaluation reporting standards

CONSORT

:   Consolidated standards of reporting trials

COSMIN

:   Consensus-based standards for the selection of health measurement instruments

CPG

:   Clinical practice guideline

DSU

:   Decision support unit

DTA

:   Diagnostic test accuracy

EBM

:   Evidence-based medicine

EPOC

:   The effective practice and organisation of care group

GRACE

:   The good research for comparative effectiveness initiative

IHE

:   Canada institute of health economics

IOM

:   Institute of medicine

JBI

:   Joanna Briggs Institute

MINORS

:   Methodological index for non-randomized studies

NICE

:   National institute for clinical excellence

NIH

:   National institutes of health

NMA

:   Network meta-analysis

NOS

:   Newcastle-Ottawa scale

OQAQ

:   Overview quality assessment questionnaire

PEDro

:   Physiotherapy evidence database

PROBAST

:   The prediction model risk of bias assessment tool

PROM

:   Patient - reported outcome measure

QIPS

:   Quality in prognosis studies

QUADAS

:   Quality assessment of diagnostic accuracy studies

RCT

:   Randomized controlled trial

RoB

:   Risk of bias

ROBINS-I

:   Risk of bias in non-randomised studies - of interventions

ROBIS

:   Risk of bias in systematic review

SIGN

:   The Scottish intercollegiate guidelines network

SQAC

:   Sack's quality assessment checklist

STAIR

:   Stroke therapy academic industry roundtable

STROBE

:   Strengthening the reporting of observational studies in epidemiology

SYRCLE

:   Systematic review center for laboratory animal experimentation
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